There are over 700 biotechs and trade sources say only about 2.5% have any deal in year -- that's a low probability of a biotech having a deal and certainly not an OTC biotech penny stock. Haven't found a single OTC biotech penny stock doing a BP deal in the last decade. So if a BP deal is a NWBO investment thesis, the odds say it is highly unlikely.
OTC penny stock companies with 12 years of accounting irregularities sanctioned by the SEC, is insolvent, in numerous litigations (including shareholder class action suit), who's Phase 3 trial publication has been challenged by other peer-reviewed article (Neuro-Oncology Journal) are unlikely to pass any BP due diligence.